Healthcare provider profile · identity verified

Jodi E. Indes, M.D.

Internal Medicine · GUILFORD, CT · NPI 1871566638

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	439	129
Amlodipine Besylate	Amlodipine Besylate	427	121
Atorvastatin Calcium	Atorvastatin Calcium	369	111
Levothyroxine Sodium	Levothyroxine Sodium	296	86
Valsartan	Valsartan	215	56
Hydrochlorothiazide	Hydrochlorothiazide	196	65
Gabapentin	Gabapentin	184	42
Lisinopril	Lisinopril	171	54
Lorazepam	Lorazepam	170	60
Metoprolol Succinate	Metoprolol Succinate	153	48
Losartan Potassium	Losartan Potassium	144	43
Escitalopram Oxalate	Escitalopram Oxalate	142	42
Trazodone Hcl	Trazodone Hcl	128	38
Simvastatin	Simvastatin	122	39
Omeprazole	Omeprazole	110	31
Alprazolam	Alprazolam	103	31
Pantoprazole Sodium	Pantoprazole Sodium	79	28
Meloxicam	Meloxicam	68	27
Sertraline Hcl	Sertraline Hcl	68	19
Bupropion Xl	Bupropion Hcl	67	17
Clonazepam	Clonazepam	67	16
Tramadol Hcl	Tramadol Hcl	65	21
Duloxetine Hcl	Duloxetine Hcl	63	13
Alendronate Sodium	Alendronate Sodium	60	17
Fluticasone Propionate	Fluticasone Propionate	57	29
Metformin Hcl Er	Metformin Hcl	57	18
Metformin Hcl	Metformin Hcl	56	15
Valacyclovir	Valacyclovir Hcl	55	24
Fluoxetine Hcl	Fluoxetine Hcl	53	15
Ibandronate Sodium	Ibandronate Sodium	53	14
Estradiol	Estradiol	50	22
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	48	40
Eliquis	Apixaban	46	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	46	12
Albuterol Sulfate Hfa	Albuterol Sulfate	45	27
Venlafaxine Hcl Er	Venlafaxine Hcl	45	suppressed
Allopurinol	Allopurinol	44	13
Azithromycin	Azithromycin	44	38
Citalopram Hbr	Citalopram Hydrobromide	44	14
Celecoxib	Celecoxib	43	13
Cephalexin	Cephalexin	42	35
Ezetimibe	Ezetimibe	42	15
Prednisone	Prednisone	42	29
Zolpidem Tartrate	Zolpidem Tartrate	42	17
Irbesartan	Irbesartan	41	11
Ozempic	Semaglutide	41	12
Synthroid	Levothyroxine Sodium	40	12
Famotidine	Famotidine	39	14
Furosemide	Furosemide	39	14
Montelukast Sodium	Montelukast Sodium	38	12
Ondansetron Odt	Ondansetron	37	16
Doxycycline Hyclate	Doxycycline Hyclate	35	33
Ventolin Hfa	Albuterol Sulfate	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	34	suppressed
Potassium Chloride	Potassium Chloride	33	11
Olmesartan Medoxomil	Olmesartan Medoxomil	32	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	suppressed
Prolia	Denosumab	31	19
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	30	27
Carvedilol	Carvedilol	30	11
Methylprednisolone	Methylprednisolone	29	25
Atenolol	Atenolol	28	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	27	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	24	17
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	24	15
Mounjaro	Tirzepatide	24	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Klor-Con M20	Potassium Chloride	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Solifenacin Succinate	Solifenacin Succinate	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	13
Diazepam	Diazepam	21	11
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Methenamine Hippurate	Methenamine Hippurate	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Arnuity Ellipta	Fluticasone Furoate	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	11
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	13
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Premarin	Estrogens, Conjugated	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Paroxetine Er	Paroxetine Hcl	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	12	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Glipizide	Glipizide	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Ubrelvy	Ubrogepant	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error